In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

An academic study of the merger hopes to give insight into how attorneys general can strengthen certificate-of-need laws and the importance of having more power over sales. Other industry news focuses ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.